Statements (54)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:pharmaceuticals
|
gptkbp:class |
Tetracycline antibiotic
|
gptkbp:clinical_trial |
Phase III
Long-term effects study Comparative study with placebo Study on efficacy Study on safety |
gptkbp:clinical_use |
Periodontal pockets
|
gptkbp:contraindication |
Pregnancy
Lactation Hypersensitivity to minocycline |
gptkbp:dosage_form |
Powder for oral suspension
|
gptkbp:duration |
Up to 6 months
|
gptkbp:effective_date |
2001-06-29
|
gptkbp:formulation |
Microspheres
|
https://www.w3.org/2000/01/rdf-schema#label |
Arestin
|
gptkbp:indication |
Adjunct to scaling and root planing
|
gptkbp:ingredients |
gptkb:Minocycline
|
gptkbp:manufacturer |
gptkb:Ora_Pharma,_Inc.
|
gptkbp:marketed_as |
gptkb:Canada
gptkb:European_Union gptkb:United_States |
gptkbp:mechanism_of_action |
Antimicrobial
|
gptkbp:packaging |
Single-use applicator
|
gptkbp:patient_population |
Adults
Adolescents |
gptkbp:pharmacokinetics |
Localized delivery
|
gptkbp:regulatory_compliance |
FDA approved
EMA approved Health Canada approved |
gptkbp:requires |
gptkb:True
|
gptkbp:research |
Cost-effectiveness analysis
Patient satisfaction survey Effectiveness in chronic periodontitis Impact on microbiome Long-term safety profile |
gptkbp:route_of_administration |
Local delivery
|
gptkbp:service_frequency |
Once per treatment site
|
gptkbp:side_effect |
gptkb:Nausea
Diarrhea Dizziness Headache Skin rash Oral mucosal ulceration Taste disturbance Vaginal candidiasis |
gptkbp:storage |
Room temperature
|
gptkbp:treatment |
Improvement in clinical attachment level
Reduction in bleeding on probing Improvement in oral health Reduction in pocket depth |
gptkbp:used_for |
Periodontal disease
|
gptkbp:bfsParent |
gptkb:Valeant_Pharmaceuticals
|
gptkbp:bfsLayer |
6
|